寡转移非小细胞肺癌化疗联合巩固放疗的2期试验长期结局
这项前瞻性、多中心、单臂2期试验于2010年启动,入组寡转移非小细胞肺癌患者,在3至6周期铂类化疗后达到部分缓解或疾病稳定的患者接受原发灶和转移灶巩固放疗,随后仅观察。29例入组、27例适合巩固放疗,中位无进展生存期11.2个月(95%CI 7.6-15.9个月),中位总生存期28.4个月(95%CI 14.5-45.8个月),研究因入组缓慢提前关闭但达到主要终点。
要点
- 寡转移非小细胞肺癌化疗后巩固放疗,中位无进展生存期11.2个月(95%CI 7.6-15.9个月)。
- 中位总生存期28.4个月(95%CI 14.5-45.8个月)。
- 有无脑转移或淋巴结受累的患者生存结局无显著差异。
核心结论
- 对于寡转移非小细胞肺癌患者,化疗后给予巩固放疗而不给予维持化疗与令人鼓舞的长期结局相关。
研究设计与样本
- 前瞻性、多中心、单臂2期试验,2010年启动,2010年10月至2015年10月入组29例,27例适合巩固放疗。
- 寡转移疾病定义为所有疾病部位最多5个转移灶,其中活动性颅外转移灶不超过3个,允许有限纵隔淋巴结受累。
- 3至6周期铂类化疗后达到部分缓解或疾病稳定的患者接受原发灶和转移灶巩固放疗,随后仅观察。
- 主要终点为无进展生存期,次要终点为局部控制、总生存期和安全性。
- 研究因入组缓慢提前关闭,但达到主要终点成功标准,即无进展生存期大于6个月(P < .0001)。
主要发现
- 中位无进展生存期为11.2个月(95%CI 7.6-15.9个月),中位总生存期为28.4个月(95%CI 14.5-45.8个月)。
- 有无脑转移患者的无进展生存期无显著差异(P = .87),总生存期无显著差异(P = .12)。
- 有无淋巴结受累患者的无进展生存期无显著差异(P = .74),总生存期无显著差异(P = .86)。
局限性
- 研究因入组缓慢提前关闭。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Recent data indicate consolidative radiation therapy improves progression-free survival (PFS) for patients with oligometastatic non-small cell lung cancer (NSCLC). Data on long-term outcomes are limited. METHODS AND MATERIALS: This prospective, multicenter, single-arm, phase 2 trial was initiated in 2010 and enrolled patients with oligometastatic NSCLC. Oligometastatic disease was defined as a maximum of 5 metastatic lesions for all disease sites, including no more than 3 active extracranial metastatic lesions. Limited mediastinal lymph node involvement was allowed. Patients achieving a partial response or stable disease after 3 to 6 cycles of platinum-based chemotherapy were treated with CRT to the primary and metastatic sites of disease, followed by observation alone. The primary endpoint was PFS, with secondary endpoints of local control, overall survival (OS), and safety. RESULTS: Twenty-nine patients were enrolled between October 2010 and October 2015, and 27 were eligible for consolidative radiation therapy. The study was closed early because of slow accrual but met its primary endpoint for success, which was PFS >6 months (P < .0001). The median PFS (95% confidence interval) was 11.2 months (7.6-15.9 months), and the median OS was 28.4 months (14.5-45.8 months). Survival outcomes were not significantly different for patients with brain metastases (P = .87 for PFS; P = .12 for OS) or lymph node involvement (P = .74 for PFS; P = .86 for OS). CONCLUSIONS: For patients with oligometastatic NSCLC, chemotherapy followed by consolidative radiation therapy without maintenance chemotherapy was associated with encouraging long-term outcomes.
引用
- Petty WJ, Urbanic JJ, Ahmed T, et al. Long-Term Outcomes of a Phase 2 Trial of Chemotherapy With Consolidative Radiation Therapy for Oligometastatic Non-Small Cell Lung Cancer. Int J Radiat Oncol Biol Phys. 2018. PMID: 30003996. doi:10.1016/j.ijrobp.2018.06.400
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。